June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Long-term OCTA Analysis of Exudative Age-Related Macular Degeneration Eyes Treated with Low Dose Proton Beam and Intravitreal Anti-VEGF
Author Affiliations & Notes
  • Philip DeSouza
    Department of Ophthalmology, UC Davis Eye Center, Sacramento, California, United States
  • Lekha Mukkamala
    Department of Ophthalmology, UC Davis Eye Center, Sacramento, California, United States
  • Kavita K Mishra
    Department of Radiation Oncology, University of California, San Francisco, California, United States
  • Inder Daftari
    Department of Radiation Oncology, University of California, San Francisco, California, United States
  • Glenn Yiu
    Department of Ophthalmology, UC Davis Eye Center, Sacramento, California, United States
  • Ala Moshiri
    Department of Ophthalmology, UC Davis Eye Center, Sacramento, California, United States
  • Susanna S Park
    Department of Ophthalmology, UC Davis Eye Center, Sacramento, California, United States
  • Footnotes
    Commercial Relationships   Philip DeSouza, None; Lekha Mukkamala, None; Kavita Mishra, None; Inder Daftari, None; Glenn Yiu, None; Ala Moshiri, None; Susanna Park, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1802. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Philip DeSouza, Lekha Mukkamala, Kavita K Mishra, Inder Daftari, Glenn Yiu, Ala Moshiri, Susanna S Park; Long-term OCTA Analysis of Exudative Age-Related Macular Degeneration Eyes Treated with Low Dose Proton Beam and Intravitreal Anti-VEGF. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1802.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe the OCTA findings in exudative age-related macular degeneration (eAMD) eyes treated with proton beam therapy (PBT) and anti-VEGF intravitreal injections as part of a Phase I/II randomized study.

Methods : Retrospective OCTA analysis (Cirrus Angioplex, v10) of the macula of both eyes in 11 eyes with newly-diagnosed eAMD that completed a prospective, sham-controlled, double-masked study, randomized 1:1:1 to 24GyE, 16GyE, or sham radiation and treated with three monthly intravitreal ranibizumab or bevacizumab injections and as needed re-injections thereafter based on monthly examination and OCT.

Results : Mean follow-up after PBT or sham radiation was 58.8 months. Six eyes had PBT (5 had 24GyE, 1 had 16GyE; 3 contralateral eyes had eAMD), and 5 eyes had sham radiation (2 contralateral eyes had eAMD). The mean retina vascular density (RVD) of the central 1mm zone of the macula in PBT-treated eyes was 4.06 mm/mm2 and 8.54 mm/mm2 in sham-radiated eyes (p=0.06). The mean ETDRS inner-ring RVD in PBT-treated eyes was 10.33 mm/mm2 and 14.24 mm/mm2 in sham-radiated eyes (p=0.06). The mean FAZ area was 0.30 mm2 in PBT-treated eyes and 0.48 mm2 in sham-radiated eyes (p=0.24). The difference in mean RVD for the central 1mm zone of the macula between the study eye and contralateral eye was 0.525 mm/mm2 in the sham group and 2.57 mm/mm2 in the PBT-treated group (p=0.24). The mean difference in the inner-ring RVD between the study eye and contralateral eye was 0.525 mm/mm2 in the sham group and 2.13 mm/mm2 in the PBT-treated group (p=0.52). The mean difference in FAZ area between the study eye and contralateral eye was -0.26 mm2 in sham group and -0.04 mm2 in PBT-treated eyes (p=0.04). The choriocapillaris layer showed flow loss only within areas of geographic atrophy (GA) in study eyes.

Conclusions : Although there is a trend toward decreased RVD in the macula in PBT-treated eyes when compared to sham-radiated eyes, the RVD of the PBT-treated eyes was not decreased when compared to that of the contralateral eye. Similarly, the FAZ size was not increased in PBT-treated eyes treated when compared to the contralateral eye or sham-radiated eyes. No choriocapillaris loss was noted outside areas of GA in all PBT-treated eyes. The findings of this limited case series show no significant long-term adverse effect of PBT on retinal or choroidal perfusion in eyes with eAMD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×